EU Health Commissioner Olivér Várhelyi has announced that the review of the EU’s medical device regulations is now deemed inevitable, representing a significant shift from the European Commission’s prior hesitance on the issue. During his first appearance before EU health ministers, Várhelyi stated that a revisitation of these regulations is practically guaranteed, indicating a newfound commitment to addressing concerns that have emerged since the rules—established in 2017—were implemented. These regulations encompass a wide array of products, including advanced medical technologies such as X-ray machines and pacemakers, alongside common items like contact lenses and bandages. The frequent extensions to the transition period for certifying these devices have raised alarms regarding safety vulnerabilities within the current regulatory framework.
As part of this revitalized approach, the European Commission, which previously refrained from promising any specific revisions, is now set to conduct consultations on the regulations by the end of this year—accelerating the timeline from its original deadline of May 2027. Várhelyi’s remarks were clear; he emphasized the need for introspection regarding the regulatory landscape around medical devices, and how the Commission would be compelled to undergo a review in the near future. In this context, he underscored the importance of collecting robust evidence to inform any legislative alterations, a sentiment echoed in his prior statements when responding to questions posed by Members of the European Parliament (MEPs).
In light of his recent declarations, Várhelyi’s call to action gains momentum from a note tabled by France and Germany, along with backing from Ireland, Luxembourg, and Romania. Their proposal seeks urgent reforms to both medical device and in vitro diagnostic regulations, aligning with Várhelyi’s immediate priorities that focus on resolving non-legislative delays, specifically in facilitating market access for orphan medical devices, which are vital in pediatric care. This urgency exists due to the protracted time it has taken for critical products to enter the market, which has caused notable shortages. Furthermore, a draft of the Commission’s working program suggests that preliminary measures to address these matters might be rolled out within the initial 100 days of the new Commission’s term.
One of the significant barriers to efficient market access has been the sluggish designation of compliance assessment bodies, raising concerns over the potential unavailability of essential medical devices. Várhelyi has indicated a willingness to explore alternative strategies aimed at reducing costs and bureaucratic hurdles provided by current notifying bodies, which he believes can expedite the entrance of products into the marketplace. Such initial efforts signal a recognition of the pressing challenges within the medical device landscape and an intention to remedy them urgently.
However, the proposed revamp of the regulations has elicited mixed reactions from stakeholders. Várhelyi’s push for rapid intervention coincides with the stance of MedTech Europe, the EU’s manufacturers’ association, which has long advocated for a comprehensive overhaul of the regulatory framework within both short and mid-term timelines. Nevertheless, not all entities share the same sense of urgency; the European Patients’ Forum has cautioned against implementing “quick fixes” without thorough evaluations and assessments. Furthermore, a resolution passed by the European Parliament in October urged the Commission to work on revisions but recommended that any changes be preceded by careful impact assessments, emphasizing the importance of a measured approach.
The political dynamics are further complicated by divisions within the European Parliament, where parties have established conflicting priorities. The center-right European People’s Party (EPP) is championing faster reforms to address existing gaps, while liberal, green, and socialist factions advocate for a more cautious approach, insisting that any legal modifications to the medical device regulations must be well-informed by robust analysis and evaluations. This divide suggests that while there is consensus on the need for change, the pace and manner in which these changes are enacted remain contentious issues that require careful negotiation to align the various interests at play within the EU’s legislative framework.
